Effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat

被引：0
|
作者：
Khosravan, R [1 ]
Grabowski, B [1 ]
Mayer, M [1 ]
Wu, JT [1 ]
Joseph-Ridge, N [1 ]
Vernillet, L [1 ]
机构：
[1] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2005年 / 45卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
69
引用
收藏
页码：1083 / 1083
页数：1
相关论文
共 50 条
  • [1] The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase
    Khosravan, R
    Grabowski, BA
    Mayer, MD
    Wu, JT
    Joseph-Ridge, N
    Vernillet, L
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (01): : 88 - 102
  • [2] Febuxostat, a non-purine selective inhibitor of xanthine oxidase effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety.
    Khosravan, R
    Mayer, M
    Grabowski, B
    Vernillet, L
    Wu, JT
    Joseph-Ridge, N
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S337 - S337
  • [3] Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics and Safety of Carisbamate
    Moore, Kenneth
    Zannikos, Peter
    Solanki, Bhavna
    Greenspan, Andrew
    Verhaeghe, Tom
    Brashear, H. Robert
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (05): : 738 - 746
  • [4] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Charles E. Frost
    Van Ly
    Samira M. Garonzik
    [J]. Drugs in R&D, 2021, 21 : 375 - 384
  • [5] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Frost, Charles E.
    Ly, Van
    Garonzik, Samira M.
    [J]. DRUGS IN R&D, 2021, 21 (04) : 375 - 384
  • [6] Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Volunteers With Mild Hepatic Impairment
    Butler, Kathleen
    Teng, Renli
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (07): : 978 - 987
  • [7] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod
    Zhang, Peijin
    Hosein, Fareeda
    Yu, Kyungha
    Walker, Susan
    Syto, Mary
    Tirucherai, Giridhar
    Murthy, Bindu
    Tatosian, Daniel
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S843 - S843
  • [8] EFFECT OF MILD AND MODERATE HEPATIC IMPAIRMENT ON QUIZARTINIB PHARMACOKINETICS
    Zahir, H.
    Lasseter, K.
    Marbury, T.
    Rondon, J.
    Bermudez, Y.
    Gammon, G.
    Kamel, Y. Mostafa
    Said, N.
    Hsu, C.
    Abutarif, M.
    Zheng, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S20 - S20
  • [9] Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
    Kletzl, Heidemarie
    Ajmi, Hassan
    Antys, Izabela
    Heinig, Katja
    Jaber, Birgit
    Marbury, Thomas C.
    Young, Annie
    Gunther, Andreas
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (08) : 3749 - 3759
  • [10] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod
    Zhang, Peijin
    Hosein, Fareeda
    Yu, Kyungha
    Walker, Susan
    Syto, Mary
    Tirucherai, Giridhar
    Murthy, Bindu
    Tatosian, Daniel
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 976 - 976
12345